Miriam Girardini - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Frontiers in Microbiology|July 19, 2018

Challenging the Drug-Likeness Dogma for New Drug Discovery in TuberculosisDiana Machado, Miriam Girardini, Miguel Viveiros, et al.

Bioorganic & Medicinal Chemistry|March 4, 2019

Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACsMiriam Girardini, Chiara Maniaci, Scott J Hughes, et al.

ACS Medicinal Chemistry Letters|July 18, 2020

2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal ChemistryElisa Azzali, Miriam Girardini, Giannamaria Annunziato, et al.

European Journal of Medicinal Chemistry|November 18, 2022

Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatizationMiriam Girardini, Francesca Ferlenghi, Giannamaria Annunziato, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Frontiers in Microbiology|July 19, 2018

Challenging the Drug-Likeness Dogma for New Drug Discovery in TuberculosisDiana Machado, Miriam Girardini, Miguel Viveiros, et al.

Bioorganic & Medicinal Chemistry|March 4, 2019

Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACsMiriam Girardini, Chiara Maniaci, Scott J Hughes, et al.

ACS Medicinal Chemistry Letters|July 18, 2020

2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal ChemistryElisa Azzali, Miriam Girardini, Giannamaria Annunziato, et al.

European Journal of Medicinal Chemistry|November 18, 2022

Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatizationMiriam Girardini, Francesca Ferlenghi, Giannamaria Annunziato, et al.

Pageof 1